In conclusion, YTHDC1 mitigates MASLD by inhibiting the PTPN22-mediated dephosphorylation and activation of NLRP3, offering new insights into therapeutic strategies for MASLD. Here, PTPN22 is linked to metabolic dysfunction-associated steatotic liver disease.